.Attribute Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a median follow-up of 11 months, clients along with metastatic intestinal cysts that obtained biomarker-matched therapies based on circulating cyst DNA profiling showed a better scientific advantage than those getting unmatched therapy.